93 patents
Page 4 of 5
Utility
Integrin Targeting Ligands and Uses Thereof
1 Apr 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
Filed: 26 Apr 19
Utility
Integrin Targeting Ligands and Uses Thereof
11 Mar 21
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described.
Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
Filed: 23 Oct 20
Utility
Rnai Therapy for Hepatitis B Virus Infection
25 Feb 21
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. WOODDELL, David B. ROZEMA, David L. LEWIS, Darren H. WAKEFIELD, Lauren J. ALMEIDA
Filed: 9 Sep 20
Utility
Compositions and methods for inhibiting gene expression of Hif2alpha
23 Feb 21
RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described.
So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
Filed: 16 Apr 18
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
16 Dec 20
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 25 Aug 20
Reissue
Compositions and methods for inhibiting gene expression of hepatitis B virus
7 Dec 20
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene.
Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John
Filed: 18 Aug 16
Utility
Compositions and methods for inhibiting gene expression of factor XII
7 Dec 20
RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described.
Steven B. Kanner, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 2 Jun 19
Utility
Integrin Ligands and Uses Thereof
25 Nov 20
Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
Filed: 30 Oct 18
Utility
RNAi therapy for hepatitis B virus infection
19 Oct 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 30 Sep 18
Utility
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
23 Sep 20
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Filed: 30 Jan 20
Utility
RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
23 Sep 20
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene.
Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
Filed: 30 Jan 20
Utility
RNAi agents for Hepatitis B virus infection
21 Sep 20
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen Li, Rui Zhu, Christine Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
Filed: 3 Aug 17
Utility
RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1
9 Sep 20
Described herein are compositions and methods for inhibition of Asialoglycoprotein receptor 1 (ASGR1) gene expression.
Zhen Li, Tao Pei, Rui Zhu, Bruce D. Given, Stacey Melquist
Filed: 15 Oct 18
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
2 Sep 20
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 18 May 20
Utility
Compositions and Methods for Inhibiting Expression of RRM2 Genes
2 Sep 20
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene.
John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
Filed: 12 Apr 20
Utility
Compositions and Methods for Inhibiting Gene Expression of Lpa
19 Aug 20
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described.
Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
Filed: 5 May 20
Utility
Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use
1 Jul 20
RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described.
Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
Filed: 11 Sep 19
Utility
Organic Compositions to Treat EPAS1-RELATED Diseases
17 Jun 20
The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.
Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dleter Heusken, Stuart Milstein, JR., Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
Filed: 20 Jan 20
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
27 May 20
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 6 Feb 20
Utility
Compositions and methods for inhibiting gene expression of LPA
25 May 20
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described.
Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
Filed: 20 Feb 18